Inozyme Pharma logo

Inozyme PharmaNASDAQ: INZY

Profile

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

24 July 2020

Next earnings report:

07 November 2024

Last dividends:

N/A

Next dividends:

N/A
$298.59 M
-37%vs. 3y high
59%vs. sector
-vs. 3y high
-vs. sector
-26%vs. 3y high
71%vs. sector
-vs. 3y high
-vs. sector

Price

after hours | Fri, 01 Nov 2024 21:26:29 GMT
$4.45+$0.14(+3.25%)

Dividend

No data over the past 3 years
No data over the past 3 years

Analysts recommendations

Institutional Ownership

INZY Latest News

Inozyme Pharma Announces Positive Interim Data from Phase 1 SEAPORT 1 Trial of INZ-701
globenewswire.com24 October 2024 Sentiment: POSITIVE

- INZ-701 was well-tolerated and significantly increased plasma pyrophosphate (PPi) levels in patients with end-stage kidney disease (ESKD) undergoing hemodialysis; low PPi levels are associated with calciphylaxis, a rare, life-threatening complication of ESKD -

Why Analyst Says Rare Disease-Focused Inozyme Pharma Stock 'Could Be Worth A Look'
benzinga.com12 September 2024 Sentiment: POSITIVE

Stifel initiated coverage on Inozyme Pharma Inc. INZY, saying, “This under-the-radar stock could be worth a look ahead of it.”

Inozyme Pharma to Participate at the 2024 Wells Fargo Healthcare Conference
globenewswire.com29 August 2024 Sentiment: POSITIVE

BOSTON, Aug. 29, 2024 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY) (“the Company” or “Inozyme”), a clinical-stage biopharmaceutical company developing innovative therapeutics for rare diseases that affect bone health and blood vessel function, today announced that Matt Winton, Ph.D., Senior Vice President and Chief Operating Officer of Inozyme, will participate in a fireside chat at the 2024 Wells Fargo Healthcare Conference on Thursday, September 5, 2024 from 3:45-4:20 pm ET.

Inozyme Pharma Announces Presentation and Sponsored Symposium at the 11th International Conference on Children's Bone Health (ICCBH)
globenewswire.com21 June 2024 Sentiment: POSITIVE

Results from a radiographic study describing skeletal features of pediatric patients with ENPP1 Deficiency will be presented Results from a radiographic study describing skeletal features of pediatric patients with ENPP1 Deficiency will be presented

Inozyme Pharma, Inc. (INZY) Moves to Buy: Rationale Behind the Upgrade
Zacks Investment Research10 October 2023 Sentiment: POSITIVE

Inozyme Pharma, Inc. (INZY) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

3 Penny Stocks To Buy According To Insiders In August 2023
PennyStocks04 August 2023 Sentiment: POSITIVE

Penny stocks are an interesting asset class when it comes to making money in the stock market. Their inherent risk/reward makeup lends to heavy speculation and a thirst for significant gains.

Inozyme Pharma to Present at the Jefferies Healthcare Conference
GlobeNewsWire02 June 2023 Sentiment: POSITIVE

BOSTON, June 02, 2023 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of pathologic mineralization and intimal proliferation, today announced Douglas A. Treco, Ph.D., the company's chief executive officer and chairman of the board, will present at the Jefferies Healthcare Conference on Friday, June 9, 2023, from 9:30-9:55 a.m. ET.

Inozyme Pharma to Present Recently Announced Preliminary Data from Ongoing Phase 1/2 Trial in ENPP1 Deficiency at the European Calcified Tissue Society Congress (ECTS)
GlobeNewsWire14 April 2023 Sentiment: POSITIVE

BOSTON, April 14, 2023 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of pathologic mineralization and intimal proliferation, today announced Yves Sabbagh, Ph.D., the company's senior vice president and chief scientific officer, will present recently announced preliminary data from the ongoing Phase 1/2 clinical trial of INZ-701 in patients with ENPP1 Deficiency in an oral presentation on Monday, April 17 at the European Calcified Tissue Society Congress (ECTS) in Liverpool, UK.

What type of business is Inozyme Pharma?

Inozyme Pharma, Inc., a clinical-stage rare disease biopharmaceutical company, focuses on developing novel therapeutics for the treatment of vasculature, soft tissue, and skeleton diseases. The company's lead product candidate is INZ-701, a soluble, recombinant, genetically engineered, and fusion protein for the treatment of ENPP1 and ABCC6 deficiencies, as well as patients with end-stage kidney disease receiving hemodialysis. It has a license agreement with Yale University for specified therapeutic and prophylactic products. The company was incorporated in 2015 and is headquartered in Boston, Massachusetts.

What sector is Inozyme Pharma in?

Inozyme Pharma is in the Healthcare sector

What industry is Inozyme Pharma in?

Inozyme Pharma is in the Biotechnology industry

What country is Inozyme Pharma from?

Inozyme Pharma is headquartered in United States

When did Inozyme Pharma go public?

Inozyme Pharma initial public offering (IPO) was on 24 July 2020

What is Inozyme Pharma website?

https://www.inozyme.com

Is Inozyme Pharma in the S&P 500?

No, Inozyme Pharma is not included in the S&P 500 index

Is Inozyme Pharma in the NASDAQ 100?

No, Inozyme Pharma is not included in the NASDAQ 100 index

Is Inozyme Pharma in the Dow Jones?

No, Inozyme Pharma is not included in the Dow Jones index

When was Inozyme Pharma the previous earnings report?

No data

When does Inozyme Pharma earnings report?

The next expected earnings date for Inozyme Pharma is 07 November 2024